

In the application of:

Daniel E. H. AFAR, et al.

Serial No.: 09/455,486

Filing Date: 6 December 1999

For: NOVEL SERPENTINE

TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS

AND USES THEREOF

Examiner: Gary B. Nickol, Ph. D.

Group Art Unit: 1642

EXPEDITED PROCEDURE --EXAMINING GROUP 1642 20/C#

2(902

AMENDMENT UNDER 37 C.F.R. § 1.116

Box AFAssistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

This is in response to an Office Action herein mailed 2 January 2002, time for response to which was set to expire 2 April 2002. A petition for an extension of time of two (2) months until 2 June 2002 is attached along with the required fee.

Applicants greatly appreciate the consideration and thoughtfulness shown by Examiners Nickol and Caputa in an interview held on this application with the patent counsel for the assignee, Agensys, and the undersigned on March 18, 2002. Certain data were discussed at the interview, and are submitted in declaratory form herewith.

The considered claims, claims 1 and 44-48 were rejected and the rejection was made final. Careful consideration has been given to the grounds for rejection, and, taking account of the discussion at the interview, the following amendment and discussion are offered in response. Reconsideration is respectfully requested.

Enclosed is the following Exhibit A: Marked-up Version of Amendments to the Specification and Claims.